Search research articles
Contact Us
Filters
Showing results (51-60 of 59) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 59 results.
Cancer Investigation
|
September 20, 2006
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
Ulrich J M Mey, Katjana S Orlopp, Dimitri Flieger, et al.
Haematologica
|
February 29, 2020
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial
Paula Cramer, Julia V Tresckow, Sandra Robrecht, et al.
Leukemia
|
November 16, 2019
Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy
Moritz Fürstenau, Georg Hopfinger, Sandra Robrecht, et al.
BMC Cancer
|
May 30, 2019
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
Hans Salwender, Uta Bertsch, Katja Weisel, et al.
Blood Cancer Journal
|
October 20, 2025
Prospective systematic classification of causes of death in the course of multiple myeloma
Jia Xiang Jin, Britta Besemer, Büsranur Yilmaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial
Petra Langerbeins, Sandra Robrecht, Pascal Nieper, et al.
The Lancet. Haematology
|
February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Elias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Leukemia
|
June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
Katharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
The Journal of Clinical Investigation
|
December 12, 2017
Drug-perturbation-based stratification of blood cancer
Sascha Dietrich, Małgorzata Oleś, Junyan Lu, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 59) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 59 results.
Cancer Investigation
|
September 20, 2006
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
Ulrich J M Mey, Katjana S Orlopp, Dimitri Flieger, et al.
Haematologica
|
February 29, 2020
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial
Paula Cramer, Julia V Tresckow, Sandra Robrecht, et al.
Leukemia
|
November 16, 2019
Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy
Moritz Fürstenau, Georg Hopfinger, Sandra Robrecht, et al.
BMC Cancer
|
May 30, 2019
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
Hans Salwender, Uta Bertsch, Katja Weisel, et al.
Blood Cancer Journal
|
October 20, 2025
Prospective systematic classification of causes of death in the course of multiple myeloma
Jia Xiang Jin, Britta Besemer, Büsranur Yilmaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial
Petra Langerbeins, Sandra Robrecht, Pascal Nieper, et al.
The Lancet. Haematology
|
February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Elias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Leukemia
|
June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
Katharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
The Journal of Clinical Investigation
|
December 12, 2017
Drug-perturbation-based stratification of blood cancer
Sascha Dietrich, Małgorzata Oleś, Junyan Lu, et al.
Page
of 6